Protein tyrosine phosphatase non-receptor type 22 (PTPN22) is a strong susceptibility gene shared by many autoimmune diseases. The aim of this study was to explore the mechanisms underlying this relationship. We performed a comprehensive analysis of the association between PTPN22 polymorphism C1858T and autoimmune diseases. The results showed a remarkable pattern; PTPN22 C1858T was strongly associated with type I diabetes, rheumatoid arthritis, immune thrombocytopenia, generalized vitiligo with concomitant autoimmune diseases, idiopathic inflammatory myopathies, Graves' disease, juvenile idiopathic arthritis, myasthenia gravis, systemic lupus erythematosus, anti-neutrophil cytoplasmic antibody-associated vasculitis and Addison's disease. By contrast, PTPN22 C1858T showed a negligible association with systemic sclerosis, celiac disease, multiple sclerosis, psoriasis, ankylosing spondylitis, pemphigus vulgaris, ulcerative colitis, primary sclerosing cholangitis, primary biliary cirrhosis, Crohn's disease and acute anterior uveitis. Further analysis revealed a clear distinction between the two groups of diseases with regard to their targeted tissues: most autoimmune diseases showing an insignificant association with PTPN22 C1858T manifest in skin, the gastrointestinal tract or in immune privileged sites. These results showed that the association of PTPN22 polymorphism with autoimmune diseases depends on the localization of the affected tissue, suggesting a role of targeted organ variation in the disease manifestations.
INTRODUCTION
Autoimmune diseases are influenced by a combination of genetic predisposition and environmental factors and are mostly polygenic disorders to which many genes contribute. Human leukocyte antigen (HLA) loci are associated with all autoimmune diseases and are the strongest genetic factors for individual predisposition. 1 Of the non-HLA susceptibility genes, variants of protein tyrosine phosphatase non-receptor type (PTPN22) show the strongest associations with autoimmune diseases. Initially identified as a susceptibility gene for type 1 diabetes (T1D), 2 variants of PTPN22, especially C1858T, have subsequently been shown to be associated with many other autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and Graves' disease. [3] [4] [5] Given the important role of PTPN22 in many autoimmune diseases, exploration of the mechanism(s) behind this association will help us to better understand the pathogenesis of disease. The human PTPN22 gene is located on chromosome 1 and encodes a protein (called Lyp) comprising 807 amino-acid residues, 6 which contains a catalytic domain and four SH3 binding sites. The R620W mutation, resulting from the C1858T polymorphism, is located within the first SH3 binding domain of Lyp, indicating that it exerts its effects by affecting intermolecular interactions. 2 Indeed, binding of Lyp to C-terminal Src tyrosine kinase (Csk) is partially or completely disrupted, and is associated with SLE, T1D and RA. 2, 3 Vang et al. 7 reported that R620W is a gain-of-function mutation, increasing catalytic activity and acting as a potent negative regulator of T lymphocyte activation. Further studies showed that that the R620W mutation also inhibited activation of NK cell and B cell. 8, 9 Although considerable progress has been achieved in examining the function of the R620W mutation, the mechanisms underlying the association between PTPN22 and autoimmune diseases are still largely unknown. Studies in mice provided only limited information to elucidate these regulatory processes. Murine PTPN8, which represents the ortholog of human PTPN22 in mice, was successfully knocked out but the corresponding animal did not develop spontaneous autoimmune diseases. 10 There may be two reasons for this, first, R620W is a gain-offunction mutation and knockout mice (essentially a loss-offunction model) are of no help. Second, a high divergence between the human PTPN22 and mouse PTPN8 genes exists, which may result in functional differences of the molecule in both species.
With regard to the strong association between PTPN22 polymorphisms and certain autoimmune diseases, extensive studies have been undertaken to evaluate the association between PTPN22 variants and more than 20 such diseases. Although PTPN22 is the one of the strongest non-HLA susceptibility genes for T1D, RA, SLE and Graves' disease, [2] [3] [4] [5] no association has been observed between PTPN22 variants and other autoimmune diseases such as systemic sclerosis (SSc), Crohn's disease, ulcerative colitis (UC) and multiple sclerosis (MS).
Examining the association pattern between PTPN22 variants and autoimmune diseases will help us to understand the pathogenesis of individual diseases. It may also help us to understand the mechanism(s) underlying this association. Therefore, we for the first time performed a comprehensive meta-analysis to identify the association pattern between PTPN22 and autoimmune diseases. We then evaluated this association pattern in detail with the aim of shedding new light on the role of PTPN22 in autoimmune disease.
RESULTS

Frequency of the PTPN22 minor allele
The frequency of the PTPN22 C1858T minor allele varies considerably across the world (Figure 1 ). In brief, European populations or populations of European descent showed a higher frequency than other populations, and the frequency in northern Europe was higher than in the south. The highest T allele frequency (17.5%) was reported in northeast Russia, 14 followed by Finland (15.4%), 15 Ukraine (14.1%) 16 and Estonia (13.9%). 17 The frequency decreased toward the west, showing 11-13% in Poland, [18] [19] [20] 10-12% in Sweden, [21] [22] [23] Norway [24] [25] [26] and Germany, 24, [27] [28] [29] 11 .7% in Croatia, 10-11% in the Czech Republic, 30, 31 10 .7% in Slovakia, 32 9.2% in Denmark, 33 and 8-10% in the UK [34] [35] [36] [37] [38] [39] and the Netherlands. 24, [40] [41] [42] The decrease in the frequency toward the south was dramatic, with 7.75% in Hungary, 43 7.23% in Belgium, 7-8% in France, 44, 45 5-7% in Spain 46-48 and 4.1% in Romania. 49 The frequency in Italy varied from 2.1 to 5.9%.
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The lowest frequency for the PTPN22 T allele was reported in two island populations: Sassari, Italy (2.1%) 2 and Crete, Greece (2.9%).
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Outside Europe, the T allele frequency in populations of European descent in New Zealand ranged from 9.9 to 10.7%, 24, 55 and in America it ranged from 3.8 to 10.0%. 49, [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] Americans of non-European descent showed a very low T allele frequency, as low as 1.1% in Mexico. 68 North Africa had a similar T allele frequency to Turkey and the Middle East, which ranged from 2 to 3.5%; [69] [70] [71] [72] [73] [74] [75] however, PTPN22 is not polymorphic in the black African population. 76 PTPN22 is also non-polymorphic or almost non-polymorphic in some Asian populations, including Japanese, Korean, Indian and some Chinese populations. [77] [78] [79] [80] [81] Two Chinese populations, Uygers and Kazaks, showed relatively high T allele frequencies of 5.3% and 7.0%, respectively; both are Caucasianrelated populations. 81 Diseases showing a strong association with PTPN22 Although not proven, it is believed that the PTPN22 C1858T polymorphism is the main causal mutation for previously described associations of PTPN22 with autoimmune diseases. 82 Therefore, we focused this meta-analysis only on the C1858T polymorphism. Due to dramatic differences in the frequency of the T allele between populations, most case-control studies have been conducted in European populations and populations of European descent. Only a few studies have been conducted in other populations such as North African, Turkish, Mexican and Indian, and then with only a small number of samples. [70] [71] [72] 74, 75, 83, 84 Therefore, to avoid any possible heterogeneity, we excluded these studies and focused on studies in European or European-descended populations.
The association between PTPN22 C1858T and autoimmune diseases was first identified in individuals with T1D in 2004. 2 Numerous studies have been performed across the world to confirm this association. Twenty-three case-control studies were recruited for this meta-analysis with odds ratios (ORs) ranging from 1.04 to 3.15. (Figure 2a ). As the most common autoimmune disease, RA is also the most extensively investigated in terms of its association with PTPN22 C1858T. In total, 36 case-control studies were recruited for the present study with ORs ranging from 0.99 to 2.56. 3, 14, 15, 18, 22, 24, 26, 28, 32, 35, [39] [40] [41] [42] 54, 60, 67, [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] Thirty-one out of thirty-six showed a significant association between PTPN22 and RA. Meta-analysis showed a strong association between the T allele and RA (OR ¼ 1.65; 95% CI ¼ 1.58-1.71, Po1.00 Â 10 À 16 ) (Figure 2b ).
Another common autoimmune disease, SLE has also been extensively studied. Of the 14 case-control studies recruited for this study, 4, 54, 60, [103] [104] [105] [106] [107] [108] 9 showed a significant association between PTPN22 C1858T and SLE. Meta-analysis showed a strong association between the T allele and SLE (OR ¼ 1.46; 95% CI ¼ 1.31-1.62, P ¼ 7.33 Â 10-13), although this was not as strong as that between T1D and PTPN22 C1858T or RA and PTPN22 C1858T (Figure 2c ).
Even though it has not been not extensively evaluated, a strong association between Graves' disease and PTPN22 C1858T has also been observed. All three case-control studies recruited for this meta-analysis showed a significant association between PTPN22 C1858T and Graves' disease with ORs ranging from 1.43 to1.88. 5, 20, 109 Meta-analysis showed a strong association between the T allele and Graves' disease (OR ¼ 1.59; 95% CI ¼ 1.37-1.85,
) (Figure 2d ). Six case-control studies evaluated the association between PTPN22 C1858T and Addison's disease. Three showed a significant association, whereas the other three studies showed a tendency toward a positive association but failed to reach the significance threshold. 25, 87, 109, 110 Meta-analysis showed a significant association between the T allele and Addison's disease (OR ¼ 1.43; 95% CI ¼ 1.21-1.68, P ¼ 2.36 Â 10 À 5 ) (Figure 2e ). Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis includes Wegener's granulomatosis, microscopic polyangiitis and Churg-Strauss syndrome. Two case-control studies were recruited for this meta-analysis. 111, 112 Meta-analysis showed a significant association between the T allele and ANCA-associated vasculitis (OR ¼ 1.45; 95% CI ¼ 1.24-1.69, P ¼ 3.07 Â 10 À 6 ) ( Figure 2f ). Seven case-control studies were undertaken to investigate the association between PTPN22 C1858T and juvenile idiopathic arthritis (JIA), five of which revealed a significant association. 15, 30, 43, 66, 103, 113 Meta-analysis showed a highly significant association between the T allele and JIA (OR ¼ 1.54; 95% CI ¼ 1.40-1.70, Po1.00 Â 10 À 16 ) ( Figure 2g ).
Only two case-control studies evaluated the association between generalized vitiligo (GV) and PTPN22 C1858T and both were recruited for the meta-analysis. Both studies suggested an association between GV and PTPN22 C1858T. 34, 49 Meta-analysis showed a strong association between the T allele and GV (OR ¼ 1.98; 95% CI ¼ 1.35-2.88, P ¼ 3.70 Â 10 À 04 ) ( Figure 2h ). This association is supported by a recent genome-wide association studies (GWAS). 114 Case-control studies have also identified a strong association between PTPN22 C1858T and myasthenia gravis (MG). Metaanalysis of five studies 23, 45, 115, 116 showed a significant association between the T allele and MG (OR ¼ 1.53; 95% CI ¼ 1.31-1.80, P ¼ 1.09 Â 10 À 07 ) ( Figure 2i ).
Diseases showing no or weak association with PTPN22
After the identification of PTPN22 C1858T as a susceptibility gene for autoimmune disease, the association between PTPN22 C1858T and inflammatory bowel disease was extensively investigated, including Crohn's disease and UC. Of the 11 case-control studies in Crohn's disease patients, only 2 identified an association with PTPN22. weak association between the T allele and a reduced risk of Crohn's disease (OR ¼ 0.84; 95% CI ¼ 0.76-0.94, P ¼ 1.89 Â 10 À 3 ) (Figure 3a ). Seven case-control studies on UC patients were recruited, six of which showed no association between PTPN22 and UC. 12, 21, 29, 37, 50, 67, 117 Meta-analysis showed no association between the T allele and UC (OR ¼ 0.96; 95% CI ¼ 0.87-1.05, P ¼ 0.347) (Figure 3b ).
Another extensively studied disease is SSc, an autoimmune disease causing extensive fibrosis and vascular alterations in the skin. 13 Eleven case-control studies have been performed, but only one identified a significant association between PTPN22 C1858T and SSc. 13, 46, 61, 118 Meta-analysis showed a very weak association between the T allele and SSc (OR ¼ 1.16; 95% CI ¼ 1.02-1.31, P ¼ 0.015) (Figure 3c ). This is consistent with the findings of a GWAS, which failed to identify an association between PTPN22 C1858T and SSc. 119 MS is a common autoimmune disease that targets the central nervous system. A study of family-based samples showed no association between PTPN22 C1858T and MS. 11 This lack of association was confirmed by a GWAS. 120 Meta-analysis of two case-control studies 96, 121 did not identify any association between PTPN22 C1858T and MS (OR ¼ 1.11; 95% CI ¼ 0.85-1.44, P ¼ 0.442) (Figure 3d ).
Another autoimmune disease, celiac disease, affects the gastrointestinal tract. No association with PTPN22 has been identified. Of the four studies recruited for this meta-analysis, three showed no association between PTPN22 C1858T and celiac disease. 42, 47, 48, 92 Meta-analysis also showed no association between PTPN22 C1858T and celiac disease (OR ¼ 1.12; 95% CI ¼ 0.97-1.29, P ¼ 0.125) (Figure 3e ).
Psoriasis also showed no association with PTPN22 C1858T according to our meta-analysis. Meta-analysis of three case-control studies with psoriasis 96, 122, 123 failed to identify any association with the T allele (OR ¼ 1.08; 95% CI ¼ 0.93-1.27, P ¼ 0.306) (Figure 3g ), which is consistent with the findings of a GWAS. 124 A psoriasis-related autoimmune disease, called psoriasis arthritis, is weakly associated with PTPN22 C1858T. Meta-analysis of four case-control studies identified a weak association between the T allele and psoriasis arthritis (OR ¼ 1.22; 95% CI ¼ 1.02-1.44, P ¼ 0.023) (Figure 3e) . 56, 96, 125 Two case-control studies have been performed for alopecia aerate (AA). One suggested a weak association with PTPN22 C1858T, but the other did not. 27, 36 Meta-analysis showed a weak association between AA and the T allele (OR ¼ 1.38; 95% CI ¼ 1.11-1.72, P ¼ 0.003) (Figure 3f ). This weak association is in line with the findings of a GWAS conducted in a Caucasian population. 126 The association between PTPN22 C1858T and primary Sjogren's syndrome (pSS) is not clear. One study from Columbia (70 cases and 308 controls) identified a strong association (OR ¼ 2.42; 95% CI ¼ 1.23-4.75, P ¼ 0.01); this was similar to that for SLE, but stronger than that for RA or T1D in the same population. 60 However, another study from France (183 cases and 172 controls) failed to show any association. 44 Meta-analysis of both these studies showed a relatively high OR for the T allele (OR ¼ 1.40; 95% CI ¼ 0.91-2.14), but it failed to reach the significance threshold (P ¼ 0.12). As no GWAS has been performed for pSS, more case-control studies are required to clarify any association between PTPN22 C1858T and pSS.
Stratified analyses based on autoantibodies The first study to report an association between RA and PTPN22 C1858T showed that it is associated with rheumatoid factor positive (RF þ ) RA but not with RF À RA, 3 raising the possibility that PTPN22 C1858T affects autoantibody production. This stratified analysis, based on autoantibody status, was performed in some of the case-control studies, allowing us to conduct a stratified meta-analysis to explore the role of PTPN22 C1858T in autoantibody production. To better evaluate the association between PTPN22 C1858T and autoantibody status, we performed stratified meta-analysis using three comparisons: antibody-positive cases vs controls, antibody-negative cases vs controls and antibody-positive cases vs antibody-negative cases (Figure 3 Figure 1a) . Five RA case-control studies based on anti-CCP antibody status were recruited for the meta-analysis. 18, 22, 28, 40, 101 The results showed a strong association between the T allele and anti-CCP þ RA (OR ¼ 1.78; 95% CI ¼ 1.59-2.01, Po1.00 Â 10 Figure 1b) .
SSc is an autoimmune disease characterized by high levels of autoantibodies against various cellular antigens including antitopoisomerase I antibodies (ATA) and anticentromere antibodies (ACA). 118 Stratified analyses have been performed based on ATA and ACA levels in 11 case-control studies. 13, 46, 61, 118 The present meta-analysis identified a marginal association between SSc and PTPN22. Stratified meta-analysis based on ATA status showed a marginal association between both ATA þ SSc (OR ¼ 1.25; 95% CI ¼ 1.03-1.54, P ¼ 0.037) and ATA À SSc (OR ¼ 1.16; 95% CI ¼ 1.00-1.33, P ¼ 0.019) and PTPN22 (Figure 4d ). Comparison between ATA þ SSc and ATA À SSc did not reveal significant differences in the T allele frequency (OR ¼ 1.11; 95% CI ¼ 0.90-1.37, P ¼ 0.323) (Supplementary Figure 1c) . Similar results were observed in the stratified meta-analysis based on ACA status, where the T allele was marginally associated with both ACA þ SSc (OR ¼ 1.28; 95% CI ¼ 1.07-1.52, P ¼ 0.0058) and ACA À SSc (OR ¼ 1.14; 95% CI ¼ 1.00-1.31, P ¼ 0.053). There was no difference in the frequency of the T allele between ACA þ SSc and ACA À SSc (OR ¼ 1.15; 95% CI ¼ 0.96-1.38, P ¼ 0.127) (Supplementary Figure 1d) . Association between PTPN22 and other autoimmune diseases Besides the autoimmune diseases mentioned above, an association between PTPN22 and several other autoimmune diseases has been investigated, including ankylosing spondylitis (AS), primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), idiopathic inflammatory myopathies (IIM), acute anterior uveitis (AAU), immune thrombocytopenia and pemphigus vulgaris (PV). 64, 103, [127] [128] [129] [130] [131] The results are summarized in Supplementary  Table S1 . Only one case-control study was conducted for each disease in European populations or populations of European descent, making meta-analysis impossible. However, evidence from GWAS or case-control studies conducted in other populations provides additional evidence for an association.
A case-control study performed by Orozco et al. 131 in 2005 did not find an association between PTPN22 C1858T and AS, a highly HLA B27-associated autoimmune disease. This lack of association between PTPN22 C1858T and AS was confirmed in a GWAS. 132 In addition, no association with PTPN22 C1858T was reported for another HLA B27-associated autoimmune disease, AAU. 129 PBC is an autoimmune disease characterized by the slow progressive destruction of the small bile ducts within the liver. 133 In 2006, Milkiewicz et al. 130 reported that PTPN22 was not associated with PBC in Canada. This result was confirmed by a GWAS in 2009 with samples from both the USA and Canada. 133 PSC is another autoimmune disease targeting the small bile ducts within the liver, and most patients with PSC also have UC. 134 As is the case for UC and PBC, PTPN22 is not associated with PSC. 103 PV is caused by antibodies against desmoglein 1 or desmoglein 3, resulting in the loss of cohesion between keratinocytes and subsequent skin blisters. 135 In 2011, Sachdevet et al. 64 reported no association between PTPN22 C1858T and PV, confirming a previous observation in a Tunisian population. 136 A strong association between PTPN22 C1858T and two other autoimmune diseases has been reported. Immune thrombocytopenia is characterized by antibody-mediated platelet destruction. D'silva et al. 128 reported a strong association between ITP and the PTPN22 T allele in a caucasian US population. This association was confirmed in an Egyptian population. 70 Finally, a strong association between the PTPN22 T allele and IIM was reported in a British Caucasian population. 127 Association pattern between PTPN22 and autoimmune diseases So far, the association between PTPN22 C1858T and 25 autoimmune diseases has been evaluated. Figure 4a summarizes the ORs for the T allele of the different diseases in a ranked order. The PTPN22 T allele is strongly associated with GV, ITP, T1D, RA, GD, JIA, MG, SLE, ANCA-associated vasculitis and Addison disease.
The association between pSS and PTPN22 needs further evaluation. A weak association was observed between PTPN22 and psoriasis arthritis and AA, and a negligible association was observed between PTPN22 and SSc, celiac disease, MS, psoriasis, AS, PV, UC, PSC, PBC, Crohn's disease and AAU.
To further examine the association pattern of PTPN22 C1858T with autoimmune diseases, we evaluated the relationship between association status and the target tissues affected by these autoimmune diseases. We focused on diseases showing a strong association with PTPN22 and diseases showing a negligible association with PTPN22. As a GWAS showed that PTPN22 is only associated with GV in patients also suffering from other autoimmune diseases, but not associated with GV in patients with GV alone, 114 we divided GV into two subsets, including GV with concomitant autoimmune diseases and GV without concomitant autoimmune diseases. This analysis identified a fine target tissue specificity between diseases showing a strong association with PTPN22 C1858T and diseases showing a negligible association with PTPN22 ( Figure 4b ). The target tissues of diseases showing a strong association with PTPN22 C1858T include skin (SLE and GV with other concomitant autoimmune diseases), blood (immune thrombocytopenia), pancreas (T1D and GV with other concomitant autoimmune diseases), kidney (SLE), connective tissue (RA), thyroid (GD), joint (JIA, RA, SLE and GV with other concomitant autoimmune diseases), muscle (MG and IIM), blood vessels (SLE and ANCA-associated vasculitis) and adrenal glands (Addison's disease and GV with other concomitant autoimmune diseases). The target tissues of diseases showing a negligible association with PTPN22 C1858T include skin (GV without any concomitant autoimmune diseases, SSc, psoriasis and PV), gastrointestinal tract (celiac disease, UC, Crohn's disease), bile duct (PSC and PBC), spine (AS) and two immune privileged tissues; the central nervous system (MS) and eye (AAU). Interestingly, although some tissues are the target for several autoimmune diseases, there is a clear distinction between those diseases showing a strong association with PTPN22 C1858T and those diseases showing a weak or negative association with PTPN22 C1858T. There is only one exception: skin is the target tissue for four autoimmune diseases (GV without concomitant autoimmune diseases, SSc, psoriasis and PV) that show a negligible association with PTPN22 C1858T, and two autoimmune diseases showing a strong association with PTPN22 C1858T (SLE and GV with concomitant autoimmune diseases). Notably, both SLE and GV with other concomitant autoimmune diseases target many tissues, indicating that skin might not be their specific target tissue. Therefore, when we exclude those autoimmune diseases that target several tissues, we see a clear distinction between autoimmune diseases showing a strong association with PTPN22 C1858T and diseases showing a negligible association with PTPN22 C1858T.
DISCUSSION
The comprehensive meta-analysis carried out in the present study showed that PTPN22 C1858T is strongly associated with nine autoimmune diseases: T1D, RA, SLE, Graves' disease, Addison's disease, ANCA-associated vasculitis, JIA, MG and GV with other concomitant autoimmune diseases. Together with 2 other PTPN22 C1858T-associated diseases (ITP and IIM), which are not included in present meta-analysis, 11 autoimmune diseases are strongly associated with PTPN22 C1858T, with the T allele increasing the risk of disease. The association suggests that there may be a common mechanism shared by these diseases. Exploration of these mechanisms will greatly help us to understand the pathogenesis of the diseases.
Based on two observations, a possible underlying mechanism affecting autoantibody production by PTPN22 variants has been suggested. 82 First, some primary T-cell-mediated autoimmune diseases, for example, Crohn's disease, UC and MS, are not associated with PTPN22 C1858T, 11, 12 whereas autoantibodyassociated diseases, for example, T1D, RA and SLE, are associated. [2] [3] [4] Second, several stratified analyses show that PTPN22 C1858T is only associated with RF þ RA or anti-CCP RA þ but not with RF À RA or anti-CCP À RA. 3, 40, 101 However, although our analysis could indeed confirm this hypothesis for some diseases others did not fit into this model. Stratified metaanalysis for RA showed that PTPN22 C1858T is associated with anti-CCP þ RA but not with anti-CCP À RA, and the association between PTPN22 C1858T and RF þ RA is much stronger than that between PTPN22 C1858T and RF À RA, suggesting that the C1858T mutation might affect the production of anti-CCP antibodies and RF. By contrast, the stratified meta-analysis for SSc did not confirm an association between PTPN22 and ATA or ACA autoantibodies. Moreover, PTPN22 C1858T is not associated with autoantibody status in T1D patients. 137 Finally, PV, which is an autoimmune disease mediated by autoantibodies against desmoglein 1 and desmoglein 3, is not associated with PTPN22 C1858T; refuting the idea that PTPN22 C1858T is associated with autoantibody status. Taken together, we have to conclude that the PTPN22 C1858T polymorphism is in some but not all cases associated with the presence autoantibodies and that development of self-reacting antibodies is not direct consequence of this gene variation.
According to a second hypothesis, the variations C1858T could lead to enhanced generation of autoreactive T cells escaping thymic selection. 137 As this gain-of-function mutation weakens TCR signaling, 2, 3, 7 it is conceivable that it will result in some moderately autoreactive T cells escaping the thymic selection process. Furthermore, the C1858T variation also weakens BCR signaling in B cells 8 and, therefore, this model can be expanded to B cells as well. As a consequence, increased numbers of autoreactive T and B cells could be responsible for an enhanced risk of developing autoimmune diseases. This new model is supported by experimental evidence from a very recent breakthrough by Menard et al. 138 In this study, Menard et al. 138 showed that the R620W variation interferes with the removal of self-reacting B cells in humans by affecting both central and peripheral B-cell tolerance check points. This study clearly shows that the R620W mutation increases the generation of autoreactive B cells, which supports the above proposed model. However, because PTPN22 as a cell signaling regulator is expressed in many immune cells, it is unlikely that PTPN22 should affect only the generation of autoimmune T and B cells. Therefore, the mechanism behind the association could be much more complex than what this model proposed. Very recently, Zhang et al. 139 investigated knock-in mice and showed that the C1858T allele affects T-cell activation and positive selection, as well as the activation of dendritic-and B-cell activation. These results provide strong evidence that PTPN22 C1858T could affect autoimmune response on several levels, including generation and activation of autoimmune cells, and in many different cell types, including T and B cells and dendritic cells. Therefore, this model need to be further revised as: PTPN22 appears to have a role in autoimmune disease manifestations by affecting the generation and activation of immune cells.
Given a role of PTPN22 in generation and activation of immune cells, the question arises why several autoimmune diseases lack any association to PTPN22. Our analysis indicates that the C1858T mutation has a negligible effect on 12 autoimmune diseases: Crohn's disease, UC, celiac disease, SSc, MS, psoriasis, PSC, PBC, AS, PV, AAU and GV without other concomitant autoimmune diseases. Together with the 11 autoimmune diseases that show a strong association with PTPN22 C1858T, a remarkable distribution pattern becomes visible that suggests a novel mechanism how some diseases could be related to PTPN22 variations. If associations are considered with regard to the targeted tissues, a clear distinction between diseases showing a strong association with PTPN22 C1858T and those showing a negligible association was found. Interestingly, the target tissues for most diseases showing a negligible association with PTPN22 are skin (in GV without concomitant other autoimmune diseases, SSc, psoriasis and PV), the gastrointestinal tract (in celiac disease, UC and Crohn's disease) and some immune privileged sites such as the central nervous system (in MS) and the eye (in AAU). Compared with other tissues, both skin and the gastrointestinal tract have exposed surfaces and therefore may be more affected by environmental factors. This raises the possibility that autoimmune diseases associated with these tissues might be triggered by some environmental factor(s), for example, bacterial infection. One typical example is Crohn's disease. Nucleotide-binding oligomerization domain-containing protein 2 (NOD2), a receptor of bacterial peptidoglycan, has been identified as the strongest non-HLA susceptibility gene for Crohn's disease, 140, 141 indicating a role for bacteria in the development of this disease. Regarding immune privileged tissues, some proteins responsible for triggering the deletion of autoreactive T and B cells are not expressed in the central immune system, allowing autoreactive lymphocytes to escape from central selection. 142, 143 Under normal physiological conditions, these autoreactive T and B cells are inactive because they are unable to enter immune privileged tissues; however, when immune privilege is disturbed, these autoreactive T and B cells may gain access to these tissues and cause an autoimmune response.
Association of PTPN22 C1858T with autoimmune diseases J Zheng et al Based on previous knowledge that PTPN22 affects the generation and activation of immune cells and our own findings regarding the association pattern and target tissue specificity, we propose a new model explaining the association between PTPN22 C1858T and autoimmune diseases ( Figure 5 ). In a healthy state, some autoreactive immune cells may escape from the central immune system. However, they are not active because they show low autoreactivity, lack access to the target antigens or are suppressed by regulatory T cells. Therefore, the autoimmune response will not manifest in the organ. Autoimmune disease (as the result of a misdirected autoimmune response) may be triggered in two ways. First, autoimmune diseases can be triggered by factors acting on immune cells, resulting in the generation of autoimmune cells or activation of immune cells. This may cause unwanted autoimmune responses and a consequent development of autoimmune diseases. The second way involves factors acting on the target tissues. For example, bacterial infection or environmental noxa may lead to a proinflammatory microenvironment in the target tissue resulting in an activation of self-reactive T and B cells with principal low autoreactivity. Such factors could also be involved in the disturbance of immune privilege, for example, by changing the permeability of the brainblood barrier, enabling the entrance of autoreactive lymphocytes into these tissues and initiating autoimmune disease. Within this view, the main effect of PTPN22 in autoimmunity maybe its capacity to affect immune cells. This could explain our observation that PTPN22 C1858T appears to be strongly associated with those autoimmune diseases, which are primarily triggered by factors dysregulating immune cells, whereas no or only low association is observed in autoimmune diseases primarily triggered by factors acting on target tissues.
In summary, our comprehensive analysis reveals an extraordinary association between PTPN22 polymorphism and a defined set of autoimmune diseases, which correlates with specific target tissues, where the corresponding disease manifests. Thus, we propose a new model for the mechanism underlying the association between PTPN22 and autoimmune disease.
MATERIALS AND METHODS
Identification of eligible studies
An exhaustive search of the Medline database was performed to identify eligible studies (the last search update was August 2011). First, the key word 'PTPN22' was used for the search without any limitations, and retrieved abstracts for 498 articles. Second, we reviewed these 498 abstracts and identified relevant articles that studied the association between the PTPN22 C1858T polymorphism and autoimmune disease.
Finally, we reviewed the full text of all the relevant articles and identified eligible studies based on following criteria: (a) the study population was European or of European-descent, (b) the study was original and (c) the patients were sporadic cases. We excluded the following: (a) studies containing overlapping data, (b) studies in which the allele frequency could not be ascertained, (c) studies in which family members had been studied and (d) GWAS. Supplementary Table S2 lists all studies used for meta-analysis.
Data extraction
Data extraction was conducted independently by two authors and consensus was achieved regarding the data. The following information was collected from each study: the first author's name, the year of publication, the population of origin, the type of autoimmune disease, the number of cases and controls, the different genotypes of the cases and controls, and the number of T and C alleles in both cases and controls. For studies including subjects from different ethnic groups, only samples from Europeans or those of European descent were extracted. For studies including several independent case-control populations, each case-control population was extracted separately.
Data evaluation and statistical analysis
For the control group in each study, we assessed departures from the Hardy-Weinberg equilibrium using the w 2 -test. The allele frequencies for the PTPN22 C1858T polymorphism were determined in each study using the allele-counting method. We then examined the allelic effect of T (minor allele) vs C (major allele). The C allele was considered as the reference allele and the T allele was considered the variant allele. The OR, 95% CI and P-values were estimated for each study. Meta-analysis was performed to calculate the pooled OR, 95% CI and P-values using the fixed-effects model. 144 Statistical analysis was performed using the Comprehensive Meta-Analysis computer program (Biosta, Englewood, NJ, USA). Figure 5 . A model of the mechanism underlying the association between PTPN22 and autoimmune diseases. In healthy individuals, autoimmune response is a tolerant state and does not attack target tissue. However, the break of such tolerance can be triggered by at least two group of factors. The first group consists of factors acting on immune cells, and the other group consists of factors acting on target tissues. PTPN22 belongs to the first group.
